Abstract
Background: The Heart Failure Society of America (HFSA) and the American College of Cardiology/American Heart Association (ACC/AHA) provide guidelines for the utilization of spironolactone (S) in severe systolic heart failure (HF) and post myocardial infarction patients. Freguent monitoring of the creatinine (Cr) or creatinine clearance (CrCL) and potassium (K) levels provide insight into the renal effects of S, but little is reported regarding these levels when S is used in conjunction with other HF medications in the community setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
